A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Serum and Plasma Copy Number Detection Using Real-time PCR

10.9K views

⸱

DOI:

10.3791/56502

⸱

December 15th, 2017

 ,  ,  ,  ,  , 

In This Article

Summary

This manuscript describes the copy number variation analysis performed in serum or plasma DNA using real-time PCR approach. This method is suitable for the prediction of drug resistance in castration resistant prostate cancer patients, but it could be informative also for other diseases.

Abstract

Serum and plasma cell free DNA (cfDNA) has been shown as an informative, non-invasive source of biomarkers for cancer diagnosis, prognosis, monitoring, and prediction of treatment resistance. Starting from the hypothesis that androgen receptor (AR) gene copy number (CN) gain is a frequent event in metastatic castration resistance prostate cancer (mCRPC), we propose to analyze this event in cfDNA as a potential predictive biomarker.

We evaluated AR CN in cfDNA using 2 different real-time PCR assays and 2 reference genes (RNaseP and AGO1). DNA amount of 60 ng was used for each assay combination. AR CN gain was confirmed using Digital PCR as a more accurate method. CN variation analysis has already been demonstrated to be informative for the prediction of treatment resistance in the setting of mCRPC, but it could be useful also for other purposes in different patient settings. CN analysis on cfDNA has several advantages: it is non-invasive, rapid and easy to perform, and it starts from a small volume of serum or plasma material.

Introduction

Circulating cell free DNA (cfDNA) in blood has been demonstrated to be an optimal source of biomarkers for cancer diagnosis, prognosis, monitoring, and prediction of treatment resistance1,2. Many studies have shown a good concordance between DNA alterations (mutations, copy number variations, epigenetic modifications) in tissues and those found in corresponding plasma samples1, confirming that circulating tumor DNA (ctDNA) is informative for primary and metastatic tumor tissue alterations3. The possibility of studying ctDNA thus allows for the reconstruction of g....

Access restricted. Please log in or start a trial to view this content.

Protocol

The protocol consists of the isolation of DNA from serum or plasma samples to perform real-time PCR for copy number analysis. DNA extraction, DNA quantity control (spectrophotometer) and real-time PCR for specific targets were performed. In Figure 1, a summary of the procedures and time line are reported.

The protocol follows the guidelines of IRST Human Research Ethics Committee.

1. Serum Collection and Processing

  1. Collect approximately 5 mL whole blood in a serum tube without anticoagulant to obtain serum. Maintain blood tubes at 4 °C until processing.
  2. Cen....

Access restricted. Please log in or start a trial to view this content.

Results

Total cfDNA concentration was quantifiable by spectrophotometry for all samples analyzed, showing a median of 6.12 ng/µL (range: 2.00 - 23.71 ng/µL) for serum samples and a median of 3.21 ng/µL (range: 2.31 - 8.49 ng/µL) for plasma samples. We analyzed a total of 115 samples by real-time PCR experiments.

Test sensitivity was assessed using mixed serum DNA from patients with high or low gain for AR, and DNA from healthy .......

Access restricted. Please log in or start a trial to view this content.

Discussion

AR CN analysis in serum and plasma sample represents a new, non-invasive approach for the stratification of castration resistant prostate cancer (CRPC) patients. It has been recently demonstrated that the AR CN is able to predict outcomes in CRPC patients treated with abiraterone and enzalutamide, before and after chemotherapy7,8,9,10.

The main adva.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare no competing financial interests.

Acknowledgements

We thank Chiara Molinari and Filippo Martignano for support in data analysis.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
BD Vacutainer Serum TubesBecton Dickinson367814whole blood tube for serum
BD Vacutainer EDTA TubesBecton Dickinson366643whole blood tube for plasma
Ethanol absoluteVWRthe user could use also other companies
TaqMan Copy Number assayThermo Fisher Scientific4400291Pre-designed and validated assays with FAM-dye. We used the followig assay: AR_assay1: hs04107225 adn AR_assay2: hs04511283
TaqMan Copy Number assay (modified)Thermo Fisher Scientific4467084Pre-designed assay modified with VIC-dye: AGO1: Hs02320401_cn
TaqMan Copy Number Reference Assay, human, RNase PThermo Fisher Scientific4403326
TaqMan Universal PCR Master MixThermo Fisher Scientific4326708Master mix for Real Time PCR
QIAamp DNA Mini Kit (50)Qiagen51304DNA extraction kit
MicroAmp 96-Well PlatesThermo Fisher ScientificN8010560plates for realt time PCR
NanoDrop 1000 SpectrophotometerThermo Fisher Scientific-the user could use also other spectrophotometric methods to quantify DNA
7500 Fast Real-Time PCR SystemApplied Biosystem-the user could use also other real time instrument
CopyCaller SoftwareApplied Biosystem-Software for copy number analysis

References

  1. Salvi, S., et al. Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 9, 6549-6559 (2016).
  2. Heitzer, E., Ulz, P., Geigl, J. B. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61 (1), 112-123 (2015).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Serum PlasmaCell-free DNAAndrogen ReceptorGene Copy NumberDigital PCRProstate CancerBiomarker AnalysisBlood Sample Processing